---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000019"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:32:59.977507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction

## Summary
- Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.
- Vafseo net product revenue $6.2M Q4, $45.8M full year 2025; 800 prescribers, 91% adherence with observed dosing.
- Auryxia net rev $181.5M FY2025; generic competition expected to reduce 2026 Auryxia revenue.
- Cash $184.8M vs $51.9M year-end 2024; sufficient for at least two years.
- Pipeline: praliciguat Phase 2 FSGS started; AKB-097 basket study in 2H 2026; AKB-9090 Phase 1 in 1H 2026.

## SEC filing metadata
- accession: 0001517022-26-000019
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/0001517022-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/akba-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000019
- JSON: https://secwatch.observer/filing/0001517022-26-000019.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.